Decoding Amgen's Options Activity: What's the Big Picture?
Decoding Amgen's Options Activity: What's the Big Picture?
High-rolling investors have positioned themselves bullish on Amgen (NASDAQ:AMGN), and it's important for retail traders to take note.\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in AMGN often signals that someone has privileged information.
大戶投資者看好安進(NASDAQ:AMGN)，零售交易者應該注意。\通過Benzinga對公開期權數據的跟蹤，我們今天得知了這一動態。這些投資者的身份尚不確定，但是安進的這一重大變化通常意味着某些人擁有特權信息。
Today, Benzinga's options scanner spotted 9 options trades for Amgen. This is not a typical pattern.
今天，Benzinga的期權掃描器發現了9筆安進期權交易。這不是一個典型的模式。
The sentiment among these major traders is split, with 44% bullish and 44% bearish. Among all the options we identified, there was one put, amounting to $41,538, and 8 calls, totaling $507,807.
這些主要交易者的情緒分爲兩派，44%看好和44%看淡。在所有我們發現的期權交易中，有一個看跌期權，金額爲41,538美元，還有8個看漲期權，總計金額爲507,807美元。
Projected Price Targets
預計價格目標
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $200.0 to $320.0 for Amgen over the last 3 months.
考慮到這些合同上的成交量和持倉量，似乎鯨魚們在過去的三個月裏一直把安進的價格範圍定在200.0到320.0美元之間。
Analyzing Volume & Open Interest
分析成交量和未平倉合約
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
這些數據可以幫助您跟蹤Coinbase Glb期權的流動性和利益，以給定的行權價格爲基礎。
This data can help you track the liquidity and interest for Amgen's options for a given strike price.
這些數據可以幫助您跟蹤給定行權價格的安進期權的流動性和興趣。
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale activity within a strike price range from $200.0 to $320.0 in the last 30 days.
下面，我們可以觀察過去30天內，所有區間在200.0-320.0美元之間的安進鯨魚活動的看漲和看跌期權成交量和持倉量的變化。
Amgen 30-Day Option Volume & Interest Snapshot
安進30天期權成交量和持倉量快照
Biggest Options Spotted:
最大的期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | TRADE | BULLISH | 01/17/25 | $23.35 | $23.2 | $23.3 | $310.00 | $174.7K | 1.1K | 1 |
| AMGN | CALL | TRADE | BULLISH | 01/17/25 | $40.3 | $38.15 | $39.7 | $280.00 | $99.2K | 1.7K | 0 |
| AMGN | CALL | TRADE | BULLISH | 07/12/24 | $6.55 | $5.3 | $6.25 | $305.00 | $62.5K | 49 | 1 |
| AMGN | CALL | TRADE | NEUTRAL | 01/16/26 | $109.8 | $107.6 | $108.9 | $200.00 | $54.4K | 45 | 1 |
| AMGN | PUT | SWEEP | BEARISH | 06/21/24 | $10.65 | $10.0 | $10.65 | $312.50 | $41.5K | 203 | 1 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看漲 | 交易 | 看好 | 01/17/25 | $23.35 | $23.2 | 23.3美元 | $ 310.00 | $174.7K | 1.1千 | 1 |
| AMGN | 看漲 | 交易 | 看好 | 01/17/25 | $40.3 | $38.15 | $39.7 | $280.00 | $99.2K | 1.7K | 0 |
| AMGN | 看漲 | 交易 | 看好 | 07/12/24 | $ 6.55 | $5.3 | 6.25美元 | $305.00 | $62.5K | 49 | 1 |
| AMGN | 看漲 | 交易 | 中立 | 01/16/26 | $109.8 | $107.6 | $108.9 | 。 | $54.4K | 45 | 1 |
| AMGN | 看跌 | SWEEP | 看淡 | 06/21/24 | $10.65 | $10.0 | $10.65 | $312.50 | $41.5K | 203 | 1 |
About Amgen
關於安進
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安進是生物技術製藥領域的領導者。旗艦藥物包括增加紅細胞計數的艾普畢與阿拉尼許、增強免疫系統的奈帕姆和奈烏細胞移植因子、以及針對炎症性疾病的恩布瑞爾和歐特茲拉。安進在2006年推出了首個癌症治療藥物Vectibix，並推出了增強骨密度的藥物Prolia/Xgeva（於2010年獲批）和Evenity（於2019年獲批）。對Onyx的收購增強了該公司在治療腫瘤領域的藥物組合，其中包括Kyprolis。最近推出的藥物包括Repatha（降低膽固醇）、Aimovig（緩解偏頭痛）、Lumakras（治療肺癌）以及Tezspire（治療哮喘）。2023年Horizon收購帶來了幾種罕見疾病藥物，其中包括治療甲狀腺眼病的Tepezza。安進還擁有不斷增長的生物類似物組合。
After a thorough review of the options trading surrounding Amgen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
經過對安進周邊期權交易的全面評估，我們轉而更加詳細地審查該公司。這包括對其當前的市場狀態和表現的評估。
Current Position of Amgen
安進的當前位置
- With a trading volume of 996,756, the price of AMGN is up by 0.16%, reaching $301.17.
- Current RSI values indicate that the stock is may be oversold.
- Next earnings report is scheduled for 50 days from now.
- 安進的交易量爲996,756，價格上漲0.16%，達到301.17美元。
- 當前RSI指標表明該股可能被超賣。
- 下一份收益報告將在50天后發佈。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期權與僅交易股票相比是一種更具風險的資產，但它們具有更高的利潤潛力。認真的期權交易者通過每日學習，進出交易，跟隨多個指標並密切關注市場來管理這種風險。
譯文內容由第三人軟體翻譯。